Biotech up­start gets $50M to test new virus-based ther­a­pies against sol­id tu­mors

The team at On­coMyx is try­ing to lever­age one ther­a­peu­tic to treat sev­er­al forms of can­cer, us­ing the Myx­o­ma virus. Wednes­day, it an­nounced the clos­ing of a $50 mil­lion Se­ries B fi­nanc­ing to take it a step clos­er to that goal.

The round was co-led by Lu­mi­ra Ven­tures and B Cap­i­tal Group with par­tic­i­pa­tion from LYZZ Cap­i­tal and its Se­ries A in­vestors Boehringer In­gel­heim Ven­ture Fund, De­los Cap­i­tal, Xer­aya Cap­i­tal, Ko­rea In­vest­ment Part­ners, City Hill Ven­tures, and Madi­son Part­ners. Beni Rovin­s­ki, the man­ag­ing di­rec­tor at Lu­mi­ra Ven­tures, and Widya Mulyasas­mi­ta, the se­nior prin­ci­pal of health­care at B Cap­i­tal Group, will join the com­pa­nies board of di­rec­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER